Evaluation of MeltPro Assay in Identification of Second-Line Injectable Drug Resistance in Multidrug-Resistant Tuberculosis Isolates
Yan Hu,Min Yu,Guoqing You,Jun Fan,Huiwen Zheng
DOI: https://doi.org/10.2147/idr.s459142
2024-05-25
Infection and Drug Resistance
Abstract:Yan Hu, 1 Min Yu, 1 Guoqing You, 1 Jun Fan, 1 Huiwen Zheng 2 1 Tuberculosis Reference Laboratory, Chongqing Tuberculosis Control Institute, Chongqing, People's Republic of China; 2 Laboratory of Respiratory Diseases, Beijing Key Laboratory of Pediatric Respiratory Infection Diseases, Beijing Pediatric Research Institute, Beijing Children's Hospital, Capital Medical University, Key Laboratory of Major Diseases in Children, Ministry of Education, National Clinical Research Center for Respiratory Diseases, National Center for Children's Health, Beijing, People's Republic of China Correspondence: Jun Fan; Huiwen Zheng, Email ; Objective: We compared the MeltPro assay to whole-genome sequencing (WGS) to investigate the molecular characterization of second-line injectable drug (SLID) resistance in multidrug-resistant tuberculosis (MDR-TB) isolates in Chongqing, China. Methods: A total of 122 MDR-TB patient isolates were collected between March 2019 and June 2020 from Chongqing Municipality, China. Conventional drug-susceptibility testing was performed using the proportion method, followed to generate minimum inhibitory concentrations (MICs) of SLIDs determined by microplate alamarblue assay. All strains were subjected to both MeltPro and WGS assays. Results: Among 122 MDR-TB isolates, 30 (24.6%), 22 (18.0%), and 14 (11.5%) were resistant to kanamycin (KM), amikacin (AM), and capreomycin (CM), respectively. Of the 31 SLID-resistant isolates, 24 (77.4%, 24/31) isolates harbored mutations in the rrs gene, with the most prevalent mutations in rrs A1401G (22/24, 91.7%). Mutation in rrs A1401G was associated with high levels of resistance to KM (MIC, ≥ 40 μg/mL) and AM (MIC, ≥ 64 μg/mL), but disparities in CM-resistance levels. Using phenotypic drug-susceptibility testing as gold standard, we found that the overall sensitivity of MeltPro and WGS was 87.1% and 90.32% and specificity 100% and 97.8%, respectively. Seven isolates had discordant results between phenotypic and genotypic resistance of SLIDs. Conclusion: MeltPro is a promising diagnostic tool for accurate identification of SLID-resistant MTB isolates with mutations in the rrs and eis genes. There was a disparity between MeltPro with WGS results in the proportion of heterogeneous drug-resistant bacteria with rrs mutation and limited probes. Resistance mechanisms other than genetic mutations will affect the consistency of MeltPro and WGS with phenotypic drug-susceptibility results. Keywords: MDR, MeltPro, resistance, genotype The prevalence of multidrug-resistant tuberculosis (MDR-TB), with an estimated of 0.41 million new cases in 2022, poses significant challenges to the prevention and control of TB disease globally. 1 MDR-TB patients are difficult to treat, and the treatment success rate was only 60% in 2021. 1 China has the second-greatest number of MDR-TB cases in the world, and the treatment success rate is only 54%. 2 Effective anti-TB medications are essential for the treatment of MDR-TB. All-oral drugs are recommended in place of second-line injectable drugs (SLIDs), with the exception of amikacin due to several adverse events, for longer MDR-TB treatment in a 2018 guideline issued by the World Health Organization (WHO). 3 Though the role of SLIDs has weakened, they should be considered as an alternative treatment when patients have limited access to all-oral drugs or have severe adverse reactions, such as with bedaquiline (BDQ). There is limited access to BDQ due to its high price in many countries, including China, and intolerance to BDQ in many patients. 4 SLIDs are still emphasized as core drug treatment in standard short-course chemotherapy regimens, and they can prevent bacterial resistance to the core drug, thus providing the most effective protection. 5,6 Second-line injections have been used in China for many years and play a certain role in the treatment of MDR-TB, so they are still in mainstream use. The diagnosis of drug-resistant TB by phenotypic drug-susceptibility testing (DST) is lengthy, laborious, and expensive. 7 As such, reliable and automated molecular assays are recommended by the WHO for detecting resistance to first-line and second-line drugs. 8 The MeltPro TB assay developed by Zeesan Biotech (Xiamen, China) is an innovative molecular test for detection of resistance to SLIDs. It is based on melting curve analysis with dual-labeled, self-quenched probes to detect multiple mutations in a single reaction, making it flexible and sensitive for use for clinical practice. 9 MeltPro TB assays for detecting rifampin (RIF), isoniazid (INH), -Abstract Truncated-
pharmacology & pharmacy,infectious diseases